Australia's Zelira Therapeutics rises on Gerrman regulatory nod for insomnia medication

Zelira Therapeutics

13/07/2022 02:10

** Shares of cannabinoid-based biopharma co Zelira
Therapeutics  ZLD.AX  rise as much as 21.21% to A$2.4, highest
since April 29
    ** ZLD received formal regulatory approval from German
regulatory authority BfArM for commercialisation of its
cannabinoid-based insomnia medication Zenivol®  urn:newsml:reuters.com:*:nASXVJLv5
    ** Approval enables Zenivol® availability outside of
Australia
    ** Stock notches its sixth straight day of gains
    ** More than 29,000 shares change hands, compared with the
30-day average volume of about 18,000 shares 
    ** Stock has fallen about 66% this year as of last close

 (Reporting by Anan Ashraf in Bengaluru)
 ((Anan.Ashraf@thomsonreuters.com;))